Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Scott Zamvil, MD, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentNeurology
    Address675 Nelson Rising Lane
    San Francisco CA 94143
    Phone415-514-8199

       Biography 
       Education and Training
      Stanford UniversityM.D.School of Medicine1988

       ORNG Applications 
       Websites
       Awarded Grants
       Global Health
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol. 2014 Nov; 76(5):633-42.
        View in: PubMed
      2. Varrin-Doyer M, Shetty A, Spencer CM, Schulze-Topphoff U, Weber MS, Bernard CC, Forsthuber T, Cree BA, Slavin AJ, Zamvil SS. MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. Neurol Neuroimmunol Neuroinflamm. 2014 Aug; 1(2):e20.
        View in: PubMed
      3. Shetty A, Gupta SG, Varrin-Doyer M, Weber MS, Prod'homme T, Molnarfi N, Ji N, Nelson PA, Patarroyo JC, Schulze-Topphoff U, Fogal SE, Forsthuber T, Sobel RA, Bernard CC, Slavin AJ, Zamvil SS. Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE. Neurol Neuroimmunol Neuroinflamm. 2014 Aug; 1(2):e22.
        View in: PubMed
      4. Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS. Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. J Neuroinflammation. 2014; 11(1):29.
        View in: PubMed
      5. Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil SS. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013 Dec 16; 210(13):2921-37.
        View in: PubMed
      6. Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013 Oct; 70(10):1315-24.
        View in: PubMed
      7. Schulze-Topphoff U, Casazza S, Varrin-Doyer M, Michel K, Sobel RA, Hauser SL, Oksenberg JR, Zamvil SS, Baranzini SE. Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. J Exp Med. 2013 Jul 1; 210(7):1301-9.
        View in: PubMed
      8. Hertzenberg D, Lehmann-Horn K, Kinzel S, Husterer V, Cravens PD, Kieseier BC, Hemmer B, Brück W, Zamvil SS, Stüve O, Weber MS. Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. Eur J Immunol. 2013 Aug; 43(8):2078-88.
        View in: PubMed
      9. Cravens PD, Kieseier BC, Hussain R, Herndon E, Arellano B, Ben LH, Timmons BC, Castro-Rojas C, Hartung HP, Hemmer B, Weber MS, Zamvil SS, Stüve O. The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation. 2013; 10:67.
        View in: PubMed
      10. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012 Jul; 72(1):53-64.
        View in: PubMed
      11. Brück W, Zamvil SS. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Clin Pharmacol. 2012 May; 5(3):245-56.
        View in: PubMed
      12. Jukkola PI, Lovett-Racke AE, Zamvil SS, Gu C. K+ channel alterations in the progression of experimental autoimmune encephalomyelitis. Neurobiol Dis. 2012 Aug; 47(2):280-93.
        View in: PubMed
      13. Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil SS. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One. 2012; 7(3):e33797.
        View in: PubMed
      14. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012 Apr 10; 78(15):1171-8.
        View in: PubMed
      15. Steinman L, Zamvil SS. Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica. Ann Neurol. 2012 Mar; 71(3):287-8.
        View in: PubMed
      16. von Büdingen HC, Bar-Or A, Zamvil SS. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol. 2011 Dec; 23(6):713-20.
        View in: PubMed
      17. Zamvil SS, Steinman L. Combining statins with interferon ß in multiple sclerosis: think twice, it might not be all right. Lancet Neurol. 2011 Aug; 10(8):672-3.
        View in: PubMed
      18. Cravens PD, Hussain RZ, Zacharias TE, Ben LH, Herndon E, Vinnakota R, Lambracht-Washington D, Nessler S, Zamvil SS, Eagar TN, Stüve O. Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. J Neuroinflammation. 2011; 8:73.
        View in: PubMed
      19. Kim SS, Richman DP, Zamvil SS, Agius MA. Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. J Neurol Sci. 2011 Jul 15; 306(1-2):9-15.
        View in: PubMed
      20. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011 May; 25(5):401-14.
        View in: PubMed
      21. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011; 6(2):e16664.
        View in: PubMed
      22. Li L, Zhang H, Varrin-Doyer M, Zamvil SS, Verkman AS. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J. 2011 May; 25(5):1556-66.
        View in: PubMed
      23. Weber MS, Benkhoucha M, Lehmann-Horn K, Hertzenberg D, Sellner J, Santiago-Raber ML, Chofflon M, Hemmer B, Zamvil SS, Lalive PH. Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One. 2010; 5(12):e16009.
        View in: PubMed
      24. Nelson PA, Khodadoust M, Prodhomme T, Spencer C, Patarroyo JC, Varrin-Doyer M, Ho JD, Stroud RM, Zamvil SS. Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One. 2010; 5(11):e15050.
        View in: PubMed
      25. Steinman L, Zamvil SS. Delivery of myelin peptides through the first line of defense, skin, to counter autoimmunity in multiple sclerosis. Ann Neurol. 2010 Nov; 68(5):567-9.
        View in: PubMed
      26. Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil SS. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010 Sep; 68(3):369-83.
        View in: PubMed
      27. Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol. 2010 Aug; 67(8):923-30.
        View in: PubMed
      28. Newell MK, Tobin RP, Cabrera JH, Sorensen MB, Huckstep A, Villalobos-Menuey EM, Burnett M, McCrea E, Harvey CP, Buddiga A, Bar-Or A, Freedman MS, Nalbantoglu J, Arbour N, Zamvil SS, Antel JP. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leukoc Biol. 2010 Oct; 88(4):779-89.
        View in: PubMed
      29. Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, Eagar TN. Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol. 2010 Nov; 67(11):1307-15.
        View in: PubMed
      30. Slavin AJ, Zamvil SS. FTY720 and central memory: out of sight, out of mind. Neurology. 2010 Aug 3; 75(5):388-9.
        View in: PubMed
      31. Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, Stüve O. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol. 2009 Aug; 66(8):1016-20.
        View in: PubMed
      32. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, Chofflon M, Zamvil SS, Lalive PH. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A. 2009 Mar 17; 106(11):4355-9.
        View in: PubMed
      33. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, Waubant E, Zamvil SS, Leppert D, Qualley P, Lincoln R, Gomez R, Caillier S, George M, Wang J, Nelson SJ, Cree BA, Hauser SL, Pelletier D. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009 Jan; 132(Pt 1):250-9.
        View in: PubMed
      34. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008 Dec; 65(12):1596-603.
        View in: PubMed
      35. Borel P, Benkhoucha M, Weber MS, Zamvil SS, Santiago-Raber ML, Lalive PH. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. Int Immunol. 2008 Oct; 20(10):1313-9.
        View in: PubMed
      36. Prod'homme T, Zamvil SS. Bench to bedside: tempering antigen-presenting cells in multiple sclerosis. Nat Med. 2008 Jun; 14(6):614-5.
        View in: PubMed
      37. Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008; 68(17):2445-68.
        View in: PubMed
      38. Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. Pharmacological treatment of early multiple sclerosis. Drugs. 2008; 68(1):73-83.
        View in: PubMed
      39. Weber MS, Zamvil SS. Statins and demyelination. Curr Top Microbiol Immunol. 2008; 318:313-24.
        View in: PubMed
      40. Fox EJ, Vartanian TK, Zamvil SS. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist. 2007 Nov; 13(6):355-62.
        View in: PubMed
      41. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007 Oct; 4(4):647-53.
        View in: PubMed
      42. Weber MS, Steinman L, Zamvil SS. Statins--treatment option for central nervous system autoimmune disease? Neurotherapeutics. 2007 Oct; 4(4):693-700.
        View in: PubMed
      43. Ransohoff RM, Zamvil SS. Neuroimmunotherapeutics comes of age. Neurotherapeutics. 2007 Oct; 4(4):569-70.
        View in: PubMed
      44. Weber MS, Stuve O, Neuhaus O, Hartung HP, Zamvil SS. Spotlight on statins. Int MS J. 2007 Sep; 14(3):93-7.
        View in: PubMed
      45. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil SS. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007 Aug; 13(8):935-43.
        View in: PubMed
      46. Costello F, Stüve O, Weber MS, Zamvil SS, Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol. 2007 Jun; 20(3):281-5.
        View in: PubMed
      47. Prod'homme T, Weber MS, Zamvil SS. T effectors outfox T regulators in autoimmunity. Nat Med. 2007 Apr; 13(4):411-3.
        View in: PubMed
      48. Kantengwa S, Weber MS, Juillard C, Benkhoucha M, Fellay B, Zamvil SS, Gougeon ML, Chofflon M, Lalive PH. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol. 2007 Apr; 185(1-2):123-9.
        View in: PubMed
      49. Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP. Simvastatin regulates oligodendroglial process dynamics and survival. Glia. 2007 Jan 15; 55(2):130-43.
        View in: PubMed
      50. Weber MS, Youssef S, Dunn SE, Prod'homme T, Neuhaus O, Stuve O, Greenwood J, Steinman L, Zamvil SS. Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol. 2006 Sep; 178(1-2):140-8.
        View in: PubMed
      51. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006 Jul; 60(1):12-21.
        View in: PubMed
      52. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006 May; 6(5):358-70.
        View in: PubMed
      53. Stüve O, Youssef S, Weber MS, Nessler S, von Büdingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest. 2006 Apr; 116(4):1037-44.
        View in: PubMed
      54. Prod'homme T, Weber MS, Steinman L, Zamvil SS. A neuropeptide in immune-mediated inflammation, Y? Trends Immunol. 2006 Apr; 27(4):164-7.
        View in: PubMed
      55. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006 Feb 20; 203(2):401-12.
        View in: PubMed
      56. Weber MS, Prod'homme T, Steinman L, Zamvil SS. Drug Insight: using statins to treat neuroinflammatory disease. Nat Clin Pract Neurol. 2005 Dec; 1(2):106-12.
        View in: PubMed
      57. Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005 Oct; 62(10):1519-30.
        View in: PubMed
      58. Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 2005 Nov; 26(11):565-71.
        View in: PubMed
      59. Menge T, von Büdingen HC, Zamvil SS, Hartung HP, Kieseier BC, Stüve O. [Statins for treatment of CNS diseases. Status report from research and clinical practice]. Nervenarzt. 2005 Apr; 76(4):426-37.
        View in: PubMed
      60. Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles. CNS Drugs. 2005; 19(10):833-41.
        View in: PubMed
      61. Vartanian TK, Zamvil SS, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5):S42-9.
        View in: PubMed
      62. Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurol. 2004 Jun; 3(6):369-71.
        View in: PubMed
      63. Stüve O, Kita M, Pelletier D, Fox RJ, Stone J, Goodkin DE, Zamvil SS. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler. 2004 Jun; 10 Suppl 1:S58-61.
        View in: PubMed
      64. Stüve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M, Hartung HP, Steinman L, Zamvil SS. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep. 2004 May; 4(3):237-44.
        View in: PubMed
      65. Stüve O, Youssef S, Dunn S, Slavin AJ, Steinman L, Zamvil SS. The potential therapeutic role of statins in central nervous system autoimmune disorders. Cell Mol Life Sci. 2003 Nov; 60(11):2483-91.
        View in: PubMed
      66. Stüve O, Prod'homme T, Slavin A, Youssef S, Dunn S, Steinman L, Zamvil SS. Statins and their potential targets in multiple sclerosis therapy. Expert Opin Ther Targets. 2003 Oct; 7(5):613-22.
        View in: PubMed
      67. Olson JK, Zamvil SS, Miller SD. Efficient technique for immortalization of murine microglial cells relevant for studies in murine models of multiple sclerosis. J Neurosci Methods. 2003 Sep 30; 128(1-2):33-43.
        View in: PubMed
      68. Pelletier D, Nelson SJ, Oh J, Antel JP, Kita M, Zamvil SS, Goodkin DE. MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J Neurol Neurosurg Psychiatry. 2003 Jul; 74(7):950-2.
        View in: PubMed
      69. Zamvil SS, Steinman L. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron. 2003 Jun 5; 38(5):685-8.
        View in: PubMed
      70. Stüve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol. 2003 Jun; 16(3):393-401.
        View in: PubMed
      71. Steinman L, Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol. 2003 Jun; 3(6):483-92.
        View in: PubMed
      72. Stüve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol. 2002 Dec 15; 169(12):6720-32.
        View in: PubMed
      73. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002 Nov 7; 420(6911):78-84.
        View in: PubMed
      74. Zamvil SS, Steinman L. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology. 2002 Oct 8; 59(7):970-1.
        View in: PubMed
      75. Soos JM, Stüve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol. 2002 Sep 1; 169(5):2231-5.
        View in: PubMed
      76. Stüve O, Cree BC, von Büdingen HC, Yousef S, Bowen JD, Genain CP, Hauser SL, Steinman L, Zamvil SS. Approved and future pharmacotherapy for multiple sclerosis. Neurologist. 2002 Sep; 8(5):290-301.
        View in: PubMed
      77. Patarroyo JC, Stuve O, Piskurich JF, Hauser SL, Oksenberg JR, Zamvil SS. Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA). Genes Immun. 2002 Feb; 3(1):34-7.
        View in: PubMed
      78. Soos JM, Krieger JI, Stüve O, King CL, Patarroyo JC, Aldape K, Wosik K, Slavin AJ, Nelson PA, Antel JP, Zamvil SS. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation. Glia. 2001 Dec; 36(3):391-405.
        View in: PubMed
      79. Slavin AJ, Soos JM, Stuve O, Patarroyo JC, Weiner HL, Fontana A, Bikoff EK, Zamvil SS. Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. J Clin Invest. 2001 Oct; 108(8):1133-9.
        View in: PubMed
      80. Genain CP, Zamvil SS. Specific immunotherapy: one size does not fit all. Nat Med. 2000 Oct; 6(10):1098-100.
        View in: PubMed
      81. Stüve O, Zamvil SS. Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. Curr Opin Neurol. 1999 Aug; 12(4):395-401.
        View in: PubMed
      82. Soos JM, Ashley TA, Morrow J, Patarroyo JC, Szente BE, Zamvil SS. Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production. Int Immunol. 1999 Jul; 11(7):1169-79.
        View in: PubMed
      83. Freedman MS, Ransohoff R, Talbot PJ, Zamvil SS. Highlights from the Fifth International Congress of the International Society of Neuroimmunology. J Neuroimmunol. 1999 Jun 1; 97(1-2):4-8.
        View in: PubMed
      84. Soos JM, Morrow J, Ashley TA, Szente BE, Bikoff EK, Zamvil SS. Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J Immunol. 1998 Dec 1; 161(11):5959-66.
        View in: PubMed
      85. Zamvil SS, Soos JM, Weiner HL. Pathogenesis and treatment of central nervous system demyelinating disease. Rev Neurol (Paris). 1998 Sep; 154(8-9):573-5.
        View in: PubMed
      86. Das MR, Cohen A, Zamvil SS, Offner H, Kuchroo VK. Prior exposure to superantigen can inhibit or exacerbate autoimmune encephalomyelitis: T-cell repertoire engaged by the autoantigen determines clinical outcome. J Neuroimmunol. 1996 Dec; 71(1-2):3-10.
        View in: PubMed
      87. Nelson PA, Akselband Y, Dearborn SM, Al-Sabbagh A, Tian ZJ, Gonnella PA, Zamvil SS, Chen Y, Weiner HL. Effect of oral beta interferon on subsequent immune responsiveness. Ann N Y Acad Sci. 1996 Feb 13; 778:145-55.
        View in: PubMed
      88. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995 Mar 10; 80(5):707-18.
        View in: PubMed
      89. Prabhu Das MR, Zamvil SS, Borriello F, Weiner HL, Sharpe AH, Kuchroo VK. Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. Eur J Immunol. 1995 Jan; 25(1):207-11.
        View in: PubMed
      90. Kuchroo VK, Collins M, al-Sabbagh A, Sobel RA, Whitters MJ, Zamvil SS, Dorf ME, Hafler DA, Seidman JG, Weiner HL, et al. T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice. J Exp Med. 1994 May 1; 179(5):1659-64.
        View in: PubMed
      91. Zamvil SS, al-Sabbagh A, Nelson PA, Kaul D, Charles MS, Mitchell DJ, Steinman L, Weiner HL, Kuchroo VK. 'Lupus-prone' mice are susceptible to organ-specific autoimmune disease, experimental allergic encephalomyelitis. Pathobiology. 1994; 62(3):113-9.
        View in: PubMed
      92. Fritz RB, Skeen MJ, Chou CH, Zamvil SS. Localization of an encephalitogenic epitope for the SJL mouse in the N-terminal region of myelin basic protein. J Neuroimmunol. 1990 Mar; 26(3):239-43.
        View in: PubMed
      93. Powell MB, Mitchell D, Lederman J, Buckmeier J, Zamvil SS, Graham M, Ruddle NH, Steinman L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol. 1990; 2(6):539-44.
        View in: PubMed
      94. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol. 1990; 8:579-621.
        View in: PubMed
      95. Sakai K, Zamvil SS, Mitchell DJ, Hodgkinson S, Rothbard JB, Steinman L. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sci U S A. 1989 Dec; 86(23):9470-4.
        View in: PubMed
      96. Davis CB, Mitchell DJ, Wraith DC, Todd JA, Zamvil SS, McDevitt HO, Steinman L, Jones PP. Polymorphic residues on the I-A beta chain modulate the stimulation of T cell clones specific for the N-terminal peptide of the autoantigen myelin basic protein. J Immunol. 1989 Oct 1; 143(7):2083-93.
        View in: PubMed
      97. Zamvil SS, Steinman L. Autoimmune demyelinating disease. West J Med. 1989 Mar; 150(3):335-6.
        View in: PubMed
      98. Sakai K, Sinha AA, Mitchell DJ, Zamvil SS, Rothbard JB, McDevitt HO, Steinman L. Involvement of distinct murine T-cell receptors in the autoimmune encephalitogenic response to nested epitopes of myelin basic protein. Proc Natl Acad Sci U S A. 1988 Nov; 85(22):8608-12.
        View in: PubMed
      99. Zamvil SS, Mitchell DJ, Powell MB, Sakai K, Rothbard JB, Steinman L. Multiple discrete encephalitogenic epitopes of the autoantigen myelin basic protein include a determinant for I-E class II-restricted T cells. J Exp Med. 1988 Sep 1; 168(3):1181-6.
        View in: PubMed
      100. Sakai K, Zamvil SS, Mitchell DJ, Lim M, Rothbard JB, Steinman L. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol. 1988 Aug; 19(1-2):21-32.
        View in: PubMed
      101. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, Zamvil SS, McDevitt HO, Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988 Jul 15; 54(2):263-73.
        View in: PubMed
      102. Zamvil SS, Mitchell DJ, Lee NE, Moore AC, Waldor MK, Sakai K, Rothbard JB, McDevitt HO, Steinman L, Acha-Orbea H. Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis. J Exp Med. 1988 May 1; 167(5):1586-96.
        View in: PubMed
      103. Trotter J, Zamvil SS, Steinman L. Comparison of antigen specificity, class II major histocompatibility complex restriction, and in vivo behavior of myelin basic protein-specific T cell lines and clones derived from (BALB/c x SJL/J) mice. J Immunol. 1987 Sep 15; 139(6):1834-9.
        View in: PubMed
      104. Zamvil SS, Mitchell DJ, Moore AC, Schwarz AJ, Stiefel W, Nelson PA, Rothbard JB, Steinman L. T cell specificity for class II (I-A) and the encephalitogenic N-terminal epitope of the autoantigen myelin basic protein. J Immunol. 1987 Aug 15; 139(4):1075-9.
        View in: PubMed
      105. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature. 1986 Nov 20-26; 324(6094):258-60.
        View in: PubMed
      106. Steinman L, Waldor MK, Zamvil SS, Lim M, Herzenberg L, Herzenberg L, McDevitt HO, Mitchell D, Sriram S. Therapy of autoimmune diseases with antibody to immune response gene products or to T-cell surface markers. Ann N Y Acad Sci. 1986; 475:274-84.
        View in: PubMed
      107. Zamvil SS, Nelson PA, Mitchell DJ, Knobler RL, Fritz RB, Steinman L. Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med. 1985 Dec 1; 162(6):2107-24.
        View in: PubMed
      108. Zamvil S, Nelson P, Trotter J, Mitchell D, Knobler R, Fritz R, Steinman L. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature. 1985 Sep 26-Oct 2; 317(6035):355-8.
        View in: PubMed
      109. Steinman L, Solomon D, Lim M, Zamvil S, Sriram S. Prevention of experimental allergic encephalitis with in vivo administration of anti I-A antibody. Decreased accumulation of radiolabelled lymph node cells in the central nervous system. J Neuroimmunol. 1983 Aug; 5(1):91-7.
        View in: PubMed
      110. Steinman L, Sriram S, Adelman NE, Zamvil S, McDevitt HO, Urich H. Murine model for pertussis vaccine encephalopathy: linkage to H-2. Nature. 1982 Oct 21; 299(5885):738-40.
        View in: PubMed
      111. Holtzman D, Nguyen H, Zamvil S, Olson J. In vitro cellular respiration at elevated temperatures in developing rat cerebral cortex. Brain Res. 1982 Aug; 256(4):401-5.
        View in: PubMed
      112. Holtzman D, Olson J, Zamvil S, Nguyen H. Maturation of potassium-stimulated respiration in rat cerebral cortical slices. J Neurochem. 1982 Jul; 39(1):274-6.
        View in: PubMed
      113. Brown JM, Twentyman PR, Zamvil SS. Response to the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. J Natl Cancer Inst. 1980 Mar; 64(3):605-11.
        View in: PubMed
      Back to TOP